Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group)

Autor:	Amelia Insa, Rosario Garcia Campelo, Ana Drozdowskyj, Bartomeu Massuti, Reyes Bernabe Caro, Rafael Rosell, Ana Laura Ortega Granados, Ana Verdu, Joaquim Bosch-Barrera, Pilar Lianes, Sergio Vazquez-Estevez, Niki Karachaliou, M. Guirado, Noemi Reguart, David Vicente, Manuel Domine, Delvys Rodriguez-Abreu, Margarita Majem, Oscar Gerardo Arrieta Rodriguez, María Ángeles Sala
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty Mutant non-small cell lung cancer (NSCLC) Phases of clinical research Olaparib 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Gefitinib Internal medicine medicine Progression-free survival Lung cancer neoplasms business.industry medicine.disease respiratory tract diseases 030104 developmental biology chemistry 030220 oncology & carcinogenesis Erlotinib business medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:9012-9012
ISSN:	1527-7755 0732-183X
Popis:	9012Background: Low BRCA1 mRNA levels correlate with longer progression free survival (PFS) in erlotinib treated EGFR mutant NSCLC patients (p), while risk of shortened PFS was associated with inte...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::90703a7ef151ab49f6be2401d6b28cad https://doi.org/10.1200/jco.2018.36.15_suppl.9012 Zobrazit plný text záznamu